



Newer Drugs in the Management of Copd

Phani Bhavana Cherukuri

Internship, Guntur medical College, INDIA

Abstract:

Chronic obstructive pulmonary disease is widespread throughout the world, especially in developing countries. It is a disorder of the lung characterized by air-flow obstruction, inflammation and tissue remodeling. Management of patients with COPD is complex and so treatment strategies are an important issue. The pharmacological treatment of chronic obstructive pulmonary disease (COPD) is offered in a variety of new single, double and triple therapies. These include short-acting beta-2 agonists, long-acting beta-2 agonists, short-acting muscarinic antagonists, long-acting muscarinic antagonists, or inhaled corticosteroids.

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines classify a patient's COPD group and provide first-line therapy options. In addition to these treatment options, other patient-specific factors are considered, such as price and type of inhaler. Triple combination-therapy inhaler, fluticasone/umeclidinium / vilanterol (Trelegy Ellipta), which provides a once-daily option for patients with more severe COPD is also included in the GOLD 2019 update. Other strategies to manage COPD include the pneumococcal vaccine, yearly influenza vaccine, antibiotics and smoking cessation.

Biography:

Phani Bhavana Cherukuri is Final year Medical Student at Guntur Medical College, Dr.N.T.R University of Health Sciences, Guntur, AP, India (August 2013- current) - Bachelor of Medicine and Bachelor of Surgery (M.B.B.S). Expected Date of Graduation : July, 2021. Her Intermediate Education [Class 11 and 12] - Sri Chaitanya Junior



College, Vijayawada (June 2011-May, 2013); GPA 9.86 in the State Intermediate Public Examination. Her High School, V.S.St. John's Higher Secondary School, Gannavaram. [Class 10] Grade A+ and GPA 10 in Central board of secondary examination.

Publication of speakers:

1. Mo, X.; Jian, W.; Su, Z.; Chen, M.; Peng, H.; Peng, P.; Lei, C.; Chen, R.; Zhong, N.; Li, S. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge.
2. Public Facebook Group: Corona Patiënten met Langdurige Klachten.
3. Herdman, M.; Gudex, C.; Lloyd, A.; Janssen, M.; Kind, P.; Parkin, D.E.; Bonsel, G.J.; Badia, X. Development and preliminary testing of the new five-level version of EQ-5D.
4. Versteegh, M.M.; Vermeulen, K.M.; Evers, S.M.A.A.; De Wit, G.A.; Prenger, H.C.; Stolk, E.A. Dutch Tariff for the Five-Level Version of EQ-5D
5. Grochtdreis, T.; Dams, J.; König, H.-H.; Konnopka, A. Health-related quality of life measured with the EQ-5D-5L: Estimation of normative index values based on a representative German population sample and value set.

[Webinar on Pulmonology and Respiratory Medicine | November 29, 2020 | London, UK](#)

Citation: Phani Bhavana Cherukuri; Newer Drugs In The Management Of Copd; Respiratory Medicine 2020 ; November 29, 2020 ; London , UK.